Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation

Blood (2025) 146 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2025-1763

Published: 2025

Journal Articles

Multiple reciprocal interactions within B-cell receptor and AKT signaling pathways regulate response to EZH2 inhibition in germinal center-derived diffuse large B-cell lymphoma

Kristyna Kupcova, Nahum Puebla, Aarthi Goverdhan, Adriana Velasova, Bree Lege, Zahid Rafiq, Victoria Roko, Esha Pisipati, Jingwei Liu, Shao-Qing Kuang, Mien-Chie Hung, Sattva Neelapu, Richard Davis, Ondrej Havranek

Blood (2025) 146 (Supplement 1): 435.

https://doi.org/10.1182/blood-2025-435

Published: 2025

Journal Articles

Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma

Jana Senavova, Tereza Chrbolkova, Eva Pokorna, Anezka Rajmonova, Vaclav Herman, Karin Ravaszova, Kristyna Kupcova, Pavel Klener, Ondrej Havranek

Blood (2025) 146 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2025-3307

Published: 2025

Journal Articles

Cell cycle dependent and independent regulation of AKT activity in germinal center B-cell-like diffuse large B-cell lymphoma – a dual role of cyclin dependent kinase 2

Anezka Rajmonova, Kristyna Kupcova, Jana Senavova, Vaclav Herman, Mariana Pacheco-Blanco, Filip Jura, Tereza Chrbolkova, Nicola Zamboni, Richard Davis, Ondrej Havranek

Blood (2025) 146 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2025-3259

Published: 2025

Journal Articles

Can Circulating Tumor DNA Improve the Predictive Value of Interim Response in Patients with Advanced Hodgkin Lymphoma and PET-2 DS3?

Heidi Mocikova, Kristyna Kupcova, Jana Markova, Lubica Gaherova, Maria Maco, Iva Hamova, Adriana Velasova, Alice Sykorova, Pavla Stepankova, Alexandra Kredatusova, Vit Prochazka, Jan Koren, Petr Nehasil, Petra Zemankova, Tomas Kozak, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 6193.

https://doi.org/10.1182/blood-2024-210890

Published: 2024

Journal Articles

Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics

Adriana Velasova, Lucie Dlouha, Iva Hamova, Kristyna Kupcova, Petra Zemankova, Petr Nehasil, Jana Senavova, Katerina Benesova, Petra Svozilkova, Jarmila Heissigerova, Marek Trneny, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 2979.

https://doi.org/10.1182/blood-2024-211732

Published: 2024

Journal Articles

Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice

Iva Hamova, Prokop Vodicka, Adriana Velasova, Kristyna Kupcova, Petra Zemankova, Petr Nehasil, Anton Tkachenko, Kamila Polgarova, Jana Salkova, Katerina Benesova, Pavel Klener, Marek Trneny, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 6235.

https://doi.org/10.1182/blood-2024-211263

Published: 2024

Journal Articles

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 230.

https://doi.org/10.1182/blood-2024-209616

Published: 2024

Journal Articles

Combinatorial PI3K/AKT Pathway Inhibition As a Therapeutic Approach in Diffuse Large B-Cell Lymphoma

Kristyna Kupcova, Jana Senavova, Vaclav Herman, Tereza Chrbolkova, Iva Ondeckova, Mariana Pacheco-Blanco, Ondrej Havranek

Blood (2022) 140 (Supplement 1): 3149–3150.

https://doi.org/10.1182/blood-2022-166121

Published: 2022

Journal Articles

Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Janneke A. Eken, Marvyn T. Koning, Julieta H. Sepulveda Yanez, Cornelis A.M. van Bergen, Edwin Quinten, Kristyna Kupcova, Ondrej Havranek, Ruben A.L. De Groen, Joost S.P. Vermaat, Daphne de Jong, Philip Kluin, Arjen Cleven, Hassan Jumaa, Hendrik Veelken

Blood (2022) 140 (Supplement 1): 6444–6445.

https://doi.org/10.1182/blood-2022-159420

Published: 2022

Journal Articles

Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-134778

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation

Multiple reciprocal interactions within B-cell receptor and AKT signaling pathways regulate response to EZH2 inhibition in germinal center-derived diffuse large B-cell lymphoma

Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma

Cell cycle dependent and independent regulation of AKT activity in germinal center B-cell-like diffuse large B-cell lymphoma – a dual role of cyclin dependent kinase 2

Can Circulating Tumor DNA Improve the Predictive Value of Interim Response in Patients with Advanced Hodgkin Lymphoma and PET-2 DS3?

Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics

Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Combinatorial PI3K/AKT Pathway Inhibition As a Therapeutic Approach in Diffuse Large B-Cell Lymphoma

Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only